ETF Holdings Breakdown of MIRM

Stock NameMirum Pharmaceuticals Inc
TickerMIRM(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS6047491013

News associated with MIRM

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $60.73 Consensus Target Price from Analysts
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) has earned a consensus recommendation of “Buy” from the twelve ratings firms that are presently covering the company, MarketBeat reports. Ten equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month price […] - 2025-06-11 05:22:45
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 16.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 73,888 shares of the company’s stock after acquiring an additional […] - 2025-06-06 07:42:48
ProShare Advisors LLC Grows Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
ProShare Advisors LLC grew its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 31.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,457 shares of the company’s stock after acquiring an additional 3,227 shares during […] - 2025-05-26 09:09:07
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $1.01 Million Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lowered its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 2.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 24,327 shares of the company’s stock after selling 498 shares during the quarter. MIRAE […] - 2025-05-26 07:38:55
Nuveen Asset Management LLC Has $29.86 Million Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
Nuveen Asset Management LLC boosted its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 46.7% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 722,155 shares of the company’s stock after buying an additional 229,746 shares during the quarter. Nuveen Asset Management LLC’s holdings in Mirum Pharmaceuticals were worth $29,861,000 as of […] - 2025-05-22 09:38:53
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Bought by Millennium Management LLC
Millennium Management LLC grew its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 15.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 526,974 shares of the company’s stock after acquiring an additional 71,410 shares during the quarter. Millennium Management LLC owned about 1.10% […] - 2025-05-21 08:46:51
HC Wainwright Reiterates Buy Rating for Mirum Pharmaceuticals (NASDAQ:MIRM)
Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued to investors on Monday, Marketbeat.com reports. They currently have a $73.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 61.01% from the company’s current price. […] - 2025-05-21 06:03:17
Comerica Bank Decreases Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
Comerica Bank lessened its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 76.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 617 shares of the company’s stock after selling 1,971 shares during the period. Comerica Bank’s […] - 2025-05-20 07:28:52
Analysts Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) PT at $58.20
Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) have been given an average recommendation of “Buy” by the eleven ratings firms that are covering the stock, Marketbeat reports. Ten research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 […] - 2025-04-22 05:34:59
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $58.20 Consensus Target Price from Analysts
Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) have earned a consensus rating of “Buy” from the eleven research firms that are presently covering the firm, MarketBeat reports. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price […] - 2025-03-28 05:34:46
AlphaQuest LLC Grows Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
AlphaQuest LLC increased its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 969.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,829 shares of the company’s stock after acquiring an additional 1,658 shares during the quarter. AlphaQuest LLC’s holdings in […] - 2025-03-20 08:04:50
Bank of New York Mellon Corp Has $5.14 Million Stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
Bank of New York Mellon Corp grew its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 8.4% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 124,328 shares of the company’s stock after acquiring an additional 9,629 shares during the period. Bank of New York Mellon Corp’s holdings in Mirum Pharmaceuticals were […] - 2025-03-18 07:09:03
Empowered Funds LLC Invests $1.38 Million in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
Empowered Funds LLC acquired a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 33,266 shares of the company’s stock, valued at approximately $1,376,000. A number of other large investors […] - 2025-02-17 08:16:48
Analysts Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Price Target at $57.10
Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) have received a consensus rating of “Buy” from the eleven ratings firms that are presently covering the company, MarketBeat reports. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average […] - 2025-02-06 06:24:49

MIRM institutional holdings

The following institutional investment holdings of MIRM have been identified

Date ETF ISIN/Name Num Shares Book value
2025-06-26 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 25,327USD 1,280,533
2025-06-26 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 2,853USD 144,248
2025-06-26 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 24,719USD 1,249,793
2025-06-26 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 24,719USD 1,249,793
2025-06-26 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 194USD 9,809
Total =77,812 USD 3,934,176
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.